The aim of this randomized double-blind placebo-controlled clinical trial was to investigate the treatment effects of intramyocardial delivered VEGF-[A.sub.165]-stimulated culture-expanded ASCs in patients with CIHD and refractory angina with preserved left ventricle ejection fraction (LVEF) > 40%.
MyStromalCell trial is a phase II, first-inman, single-center, double-blind, randomized, placebocontrolled study of intramyocardial injections of autologous ASCs in patients with CIHD and refractory angina due to at least one occluded or severely stenotic coronary artery and preserved LVEF.
Patients between 30 and 80 years of age with CIHD and refractory angina due to at least one significantly stenosed coronary artery visualized on invasive angiogram without any options for revascularization were considered for inclusion.
MystromalCell trial is the first-in-man randomized, doubleblind placebo-controlled study using VEGF-[A.sub.165]-stimulated culture-expanded ASCs for patients with refractory angina due to CIHD and preserved LVEF.
In mice with CIHD, ASC improved LVEF assessed by echocardiography and [sup.18]F-FDG microPET imaging .
Previously, bone marrow-derived MSCs have shown to reduce symptoms of patients with CIHD with and without heart failure [10, 12, 13].
Our analysis included 232,905 IHD hospitalizations (AMI: 83,650 [35.92%], AP: 10,794 [4.63%], CIHD: 100,496 [43.15%], and OIHD: 37,965 [16.3%]).
We observed a statistically significant harmful effect on hospital admissions of AMI at lag4-lag6 and for CIHD at lag6.
CIHD sued on the grounds that combining the units was contrary to law, procedurally irregular, and reduced the financial returns to the school fund.
Ruling for CIHD, the court was "not persuaded that the error [in failing to give adequate notice of the combining of the parcels] was harmless" and remanded for a new auction.